Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash & Equivalents (2024 - 2025)

Historic Cash & Equivalents for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to $95.3 million.

  • Kura Oncology's Cash & Equivalents rose 9257.68% to $95.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.3 million, marking a year-over-year increase of 9257.68%. This contributed to the annual value of $224.5 million for FY2024, which is N/A changed from last year.
  • Per Kura Oncology's latest filing, its Cash & Equivalents stood at $95.3 million for Q3 2025, which was up 9257.68% from $81.9 million recorded in Q2 2025.
  • Kura Oncology's Cash & Equivalents' 5-year high stood at $224.5 million during Q4 2024, with a 5-year trough of $41.5 million in Q1 2024.